Citizenship

Aura Biosciences to Participate in Upcoming Investor Conferences

Retrieved on: 
Mittwoch, Mai 8, 2024
Citizenship, Cancer, Doctor of Philosophy, Conference, Webcast, Fireside chats, Flour

BOSTON, May 08, 2024 (GLOBE NEWSWIRE) -- Aura Biosciences, Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing precision immunotherapies to treat solid tumors designed to preserve the function of the organ with cancer, today announced that Elisabet de los Pinos, PhD, Chief Executive Officer, will participate in the following upcoming investor conferences:

Key Points: 
  • BOSTON, May 08, 2024 (GLOBE NEWSWIRE) -- Aura Biosciences, Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing precision immunotherapies to treat solid tumors designed to preserve the function of the organ with cancer, today announced that Elisabet de los Pinos, PhD, Chief Executive Officer, will participate in the following upcoming investor conferences:
    The Citizens JMP Life Sciences Conference on Monday, May 13, 2024.
  • Fireside Chat at 9:00 a.m.
  • ET.
  • TD Cowen 5th Annual Oncology Innovation Summit on Wednesday, May 29, 2024.

BioAtla to Participate in the Citizens JMP Life Sciences Conference

Retrieved on: 
Mittwoch, Mai 8, 2024
Citizenship, Therapy, Conference, SAN, CAB, Conditional

SAN DIEGO, May 08, 2024 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today announced that the Company’s management will participate in a fireside chat and one-on-one investor meetings at the Citizens JMP Life Sciences Conference, to be held in New York, NY May 13-14, 2024.

Key Points: 
  • SAN DIEGO, May 08, 2024 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today announced that the Company’s management will participate in a fireside chat and one-on-one investor meetings at the Citizens JMP Life Sciences Conference, to be held in New York, NY May 13-14, 2024.

Lexeo Therapeutics to Participate in Upcoming Investor Conferences

Retrieved on: 
Dienstag, Mai 7, 2024
News, Citizenship, Therapy, Conference

NEW YORK, May 07, 2024 (GLOBE NEWSWIRE) -- Lexeo Therapeutics, Inc. (Nasdaq: LXEO), a clinical stage genetic medicine company dedicated to pioneering treatments for genetically defined cardiovascular diseases and APOE4-associated Alzheimer’s disease, today announced that company management will participate in fireside chats at the following investor conferences:

Key Points: 
  • NEW YORK, May 07, 2024 (GLOBE NEWSWIRE) -- Lexeo Therapeutics, Inc. (Nasdaq: LXEO), a clinical stage genetic medicine company dedicated to pioneering treatments for genetically defined cardiovascular diseases and APOE4-associated Alzheimer’s disease, today announced that company management will participate in fireside chats at the following investor conferences:
    The Citizens JMP Life Sciences Conference on Monday, May 13, 2024 at 9:00 AM ET
    RBC Capital Markets 2024 Global Healthcare Conference on Tuesday, May 14, 2024 at 11:00 AM ET
    Bank of America Securities 2024 Health Care Conference on Wednesday, May 15, 2024 at 8:40 AM PT
    The events will be webcast live under the News & Events tab in the Investors section of our website.
  • Replays of the webcasts will be available on the website following the presentations.

Arbutus to Participate in Two Upcoming Investor Conferences

Retrieved on: 
Dienstag, Mai 7, 2024
CFBV, Arbutus, Webcast, The Citizen, Citizenship, Virology, Conference, Fireside chats

WARMINSTER, Pa., May 07, 2024 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop a functional cure for people with chronic hepatitis B virus (cHBV) infection, today announced that the Arbutus management team will participate in and host one-on-one meetings at the following two upcoming investor conferences which are being held in New York:

Key Points: 
  • WARMINSTER, Pa., May 07, 2024 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop a functional cure for people with chronic hepatitis B virus (cHBV) infection, today announced that the Arbutus management team will participate in and host one-on-one meetings at the following two upcoming investor conferences which are being held in New York:
    The Citizens JMP Life Sciences Conference: Fireside Chat on May 14, 2024 at 9:30 am ET
    H.C. Wainwright 2nd Annual BioConnect Investor Conference: Fireside Chat on May 20, 2024 at 3:30 pm ET
    To access the live webcast of the fireside chats please visit: https://investor.arbutusbio.com/events-presentations .
  • An archived replay of the webcast will be available on the Arbutus website for a limited time after the event.

LAVA Therapeutics to Participate in the Citizens JMP Life Sciences Conference

Retrieved on: 
Montag, Mai 6, 2024
Citizenship, LAVA, Therapy, Conference

UTRECHT, The Netherlands and PHILADELPHIA, May 06, 2024 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (NASDAQ: LVTX, “LAVA,” or “Company”), a clinical-stage immuno-oncology company focused on developing its proprietary Gammabody® platform of bispecific gamma-delta (δ2)

Key Points: 
  • UTRECHT, The Netherlands and PHILADELPHIA, May 06, 2024 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (NASDAQ: LVTX, “LAVA,” or “Company”), a clinical-stage immuno-oncology company focused on developing its proprietary Gammabody® platform of bispecific gamma-delta (δ2)
    T cell engagers, today announced that Stephen Hurly, President and Chief Executive Officer of LAVA Therapeutics, will participate in a fireside chat at the Citizens JMP Life Sciences Conference.
  • A webcast of the fireside chat can be accessed under the "Events" tab on the investor relations section of the LAVA Therapeutics website at https://ir.lavatherapeutics.com/news-events/events .
  • The replay will be archived for 90 days following the presentation date.

OptimizeRx to Participate in Upcoming Investor Conferences 

Retrieved on: 
Montag, Mai 6, 2024
Citizenship, Patient, Conference

WALTHAM, Mass., May 06, 2024 (GLOBE NEWSWIRE) -- OptimizeRx Corp .

Key Points: 
  • WALTHAM, Mass., May 06, 2024 (GLOBE NEWSWIRE) -- OptimizeRx Corp .
  • (the “Company”) (Nasdaq: OPRX), the leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare professional (HCPs) and patients, today announced that management will participate in the following upcoming investor conferences:
    RBC Capital Markets Global Healthcare Conference, New York City, May 14 – 15, 2024
    B.Riley Securities 24th Annual Institutional Investor Conference, Beverly Hills, May 22 – 23, 2024
    Stifel Cross Sector Insight Conference, Boston, June 4 – 5, 2024
    The Citizens JMP Medical Devices and Healthcare Services Forum, Boston, June 20, 2024

Ocular Therapeutix™ to Present at Two Upcoming Investor Conferences

Retrieved on: 
Montag, Mai 6, 2024
Bank of America, Diabetic retinopathy, BofA Securities, Citizenship, Quality of life, Eye, Conference

BEDFORD, Mass., May 06, 2024 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL, “Ocular”, the “Company”), a biopharmaceutical company committed to enhancing people’s vision and quality of life through the development and commercialization of innovative therapies for wet age-related macular degeneration (wet AMD), diabetic retinopathy, and other diseases and conditions of the eye, today announced that it will participate at two investor conferences in May:

Key Points: 
  • BEDFORD, Mass., May 06, 2024 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL, “Ocular”, the “Company”), a biopharmaceutical company committed to enhancing people’s vision and quality of life through the development and commercialization of innovative therapies for wet age-related macular degeneration (wet AMD), diabetic retinopathy, and other diseases and conditions of the eye, today announced that it will participate at two investor conferences in May:
    A live webcast of the fireside chats at the Citizens JMP Life Sciences Conference and BofA Securities 2024 Health Care Conference can be accessed by visiting the Investors section of the Company’s website at investors.ocutx.com.

Sana Biotechnology to Present at May and June 2024 Investor Conferences

Retrieved on: 
Montag, Mai 6, 2024
Bank of America, BofA Securities, Citizenship, Biotechnology, Patient, Conference

SEATTLE, May 06, 2024 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today announced that it will webcast its presentations at three investor conferences in May and June.

Key Points: 
  • SEATTLE, May 06, 2024 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today announced that it will webcast its presentations at three investor conferences in May and June.
  • Sana will present at the Citizens JMP Securities Life Sciences Conference at 11:30 a.m.
  • Sana will present at the BofA Securities 2024 Healthcare Conference at 3:00 p.m. PT on Tuesday, May 14, 2024.
  • Sana will present at the Goldman Sachs 45th Annual Global Healthcare Conference at 2:40 p.m.

Savara to Present at the Citizens JMP Life Sciences Conference

Retrieved on: 
Dienstag, Mai 7, 2024
Biotechnology, Pharmaceutical, Health, Clinical Trials, Inc., Citizenship, Conference

Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that its management team will participate in a fireside chat at the Citizens JMP Life Science Conference on May 14, 2024 at 6:00am PT/9:00am ET.

Key Points: 
  • Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that its management team will participate in a fireside chat at the Citizens JMP Life Science Conference on May 14, 2024 at 6:00am PT/9:00am ET.
  • A live webcast of the fireside chat will be available on Savara’s website at www.savarapharma.com/investors/events-presentations/ and will be archived for 90 days.

Mirum Pharmaceuticals to Present at the Citizens JMP Life Sciences Conference

Retrieved on: 
Dienstag, Mai 7, 2024
Biotechnology, Pharmaceutical, Health, Acquisition, Citizenship, Medication, Conference

Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a biopharmaceutical company focused on the identification, acquisition, development and commercialization of novel therapies for debilitating rare and orphan diseases, today announced that it will present at the Citizens JMP Life Sciences Conference in New York, NY on Tuesday, May 14th at 1:30 PM EDT.

Key Points: 
  • Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a biopharmaceutical company focused on the identification, acquisition, development and commercialization of novel therapies for debilitating rare and orphan diseases, today announced that it will present at the Citizens JMP Life Sciences Conference in New York, NY on Tuesday, May 14th at 1:30 PM EDT.
  • Visit the Investors and Media section of Mirum’s corporate website for webcast links and additional information.